{
  "meta": {
    "data_length": 1,
    "message": "Statements retrieved successfully",
    "request_url": "http://api.moalmanac.org/statements?proposition_id=314&agent_id=fda&agent_id=ema",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.034983,
    "timestamp_received": "2026-04-12T06:08:46.477698+00:00Z",
    "timestamp_returned": "2026-04-12T06:08:46.512681+00:00Z",
    "trace_id": "394a36c7-ce78-4d56-83ad-0f55b640a77a"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": 365,
      "type": "Statement",
      "description": "The U.S. Food and Drug Administration granted approval to panitumumab in combination with FOLFOX for the first-line treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS, as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC). The product label specifies a limitation of use that panitumumab is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.",
      "contributions": [
        {
          "id": 0,
          "type": "Contribution",
          "agent": {
            "id": "vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute",
            "last_updated": null,
            "url": null
          },
          "description": "Initial access of FDA approvals",
          "date": "2024-10-30"
        }
      ],
      "reportedIn": [
        {
          "id": "doc:fda.vectibix",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Vectibix (panitumumab) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "Amgen, Inc. Vectibix (panitumumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf. Revised April 2021. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-04-09",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Amgen, Inc.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Vectibix",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "panitumumab",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 125147,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2021-08-25",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "indication": {
        "id": "ind:fda.vectibix:0",
        "indication": "Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC) in combination with FOLFOX for first-line treatment. Limitation of Use: Vectibix is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.",
        "initial_approval_date": "2021-08-25",
        "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf",
        "description": "The U.S. Food and Drug Administration granted approval to panitumumab in combination with FOLFOX for the first-line treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS, as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC). The product label specifies a limitation of use that panitumumab is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.",
        "raw_biomarkers": "wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use)",
        "raw_cancer_type": "metastatic colorectal cancer",
        "raw_therapeutics": "Vectibix (panitumumab) in combination with folfox",
        "icd10": null,
        "regimen_code": null,
        "reimbursement_category": null,
        "reimbursement_date": null,
        "reimbursement_details": null,
        "date_regular_approval": null,
        "date_accelerated_approval": null,
        "document": {
          "id": "doc:fda.vectibix",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Vectibix (panitumumab) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "Amgen, Inc. Vectibix (panitumumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf. Revised April 2021. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-04-09",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Amgen, Inc.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Vectibix",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "panitumumab",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 125147,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2021-08-25",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      },
      "proposition": {
        "id": 314,
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictSensitivityTo",
        "biomarkers": [
          {
            "id": 26,
            "name": "Wild type HRAS",
            "genes": [
              {
                "id": 27,
                "name": "HRAS",
                "primaryCoding": {
                  "id": "hgnc:5173",
                  "code": "HGNC:5173",
                  "name": null,
                  "system": "https://genenames.org",
                  "systemVersion": null,
                  "iris": [
                    "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5173"
                  ]
                },
                "mappings": [
                  {
                    "relation": "relatedMatch",
                    "coding": {
                      "id": "refseq:NM_005343.4",
                      "code": "NM_005343.4",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/nuccore/NM_005343.4"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ensembl:ensg00000174775",
                      "code": "ENSG00000174775",
                      "name": null,
                      "system": "https://www.ensembl.org",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ensembl.org/id/ENSG00000174775"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ncbi:3265",
                      "code": "3265",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/gene",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/gene/3265"
                      ]
                    }
                  }
                ],
                "extensions": [
                  {
                    "name": "location",
                    "value": "11p15.5"
                  },
                  {
                    "name": "location_sortable",
                    "value": "11p15.5"
                  }
                ]
              }
            ],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Wild type"
              },
              {
                "name": "present",
                "value": true
              }
            ]
          },
          {
            "id": 25,
            "name": "Wild type KRAS",
            "genes": [
              {
                "id": 31,
                "name": "KRAS",
                "primaryCoding": {
                  "id": "hgnc:6407",
                  "code": "HGNC:6407",
                  "name": null,
                  "system": "https://genenames.org",
                  "systemVersion": null,
                  "iris": [
                    "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407"
                  ]
                },
                "mappings": [
                  {
                    "relation": "relatedMatch",
                    "coding": {
                      "id": "refseq:NM_004985.5",
                      "code": "NM_004985.5",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ensembl:ensg00000133703",
                      "code": "ENSG00000133703",
                      "name": null,
                      "system": "https://www.ensembl.org",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ensembl.org/id/ENSG00000133703"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ncbi:3845",
                      "code": "3845",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/gene",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/gene/3845"
                      ]
                    }
                  }
                ],
                "extensions": [
                  {
                    "name": "location",
                    "value": "12p12.1"
                  },
                  {
                    "name": "location_sortable",
                    "value": "12p12.1"
                  }
                ]
              }
            ],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Wild type"
              },
              {
                "name": "present",
                "value": true
              }
            ]
          }
        ],
        "subjectVariant": {},
        "conditionQualifier": {
          "id": 15,
          "conceptType": "Disease",
          "name": "Colorectal Adenocarcinoma",
          "primaryCoding": {
            "id": "oncotree:COADREAD",
            "code": "COADREAD",
            "name": "Colorectal Adenocarcinoma",
            "system": "https://oncotree.mskcc.org",
            "systemVersion": "oncotree_2021_11_02",
            "iris": [
              "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD"
            ]
          },
          "mappings": []
        },
        "objectTherapeutic": {
          "id": 50,
          "membership_operator": "AND",
          "therapies": [
            {
              "id": 97,
              "conceptType": "Drug",
              "name": "Panitumumab",
              "primaryCoding": {
                "id": "ncit:C1857",
                "code": "C1857",
                "name": "Panitumumab",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1857"
                ]
              },
              "mappings": [],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "EGFR inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Targeted therapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            },
            {
              "id": 28,
              "conceptType": "Drug",
              "name": "Oxaliplatin",
              "primaryCoding": {
                "id": "ncit:C1181",
                "code": "C1181",
                "name": "Oxaliplatin",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181"
                ]
              },
              "mappings": [],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Platinum-based chemotherapy"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Chemotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            },
            {
              "id": 29,
              "conceptType": "Drug",
              "name": "Fluorouracil",
              "primaryCoding": {
                "id": "ncit:C505",
                "code": "C505",
                "name": "Fluorouracil",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"
                ]
              },
              "mappings": [],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Thymidylate synthase inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Chemotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            }
          ]
        }
      }
    }
  ]
}